THRX Stock Overview
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Theseus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.06 |
| 52 Week High | US$12.37 |
| 52 Week Low | US$2.05 |
| Beta | 3.98 |
| 1 Month Change | 0.74% |
| 3 Month Change | 18.37% |
| 1 Year Change | -63.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.15% |
Recent News & Updates
Recent updates
Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR
Feb 01Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans
Aug 18
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
May 05Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
Dec 07Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Aug 11Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation
Apr 22Shareholder Returns
| THRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.5% | -1.7% | -2.6% |
| 1Y | -63.4% | 3.2% | 24.5% |
Return vs Industry: THRX underperformed the US Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: THRX underperformed the US Market which returned 16.6% over the past year.
Price Volatility
| THRX volatility | |
|---|---|
| THRX Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THRX's share price has been volatile over the past 3 months.
Volatility Over Time: THRX's weekly volatility has decreased from 16% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 38 | n/a | theseusrx.com |
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Theseus Pharmaceuticals, Inc. Fundamentals Summary
| THRX fundamental statistics | |
|---|---|
| Market cap | US$180.72m |
| Earnings (TTM) | -US$56.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs THRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.61m |
| Earnings | -US$56.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/14 16:40 |
| End of Day Share Price | 2024/02/14 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theseus Pharmaceuticals, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Andrew Fein | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |